A Phase IV, Single-Centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2013/2014 Formulation of a bioCSL split virion, inactivated influenza vaccine in Healthy Volunteers aged 18-60 years

To evaluate the immunogenicity of the study vaccine in healthy adults aged 18 to 60 years according to the criteria outlined in the CPMP Note for Guidance on Harmonisation of Requirements for Influenza Vaccines (CPMP/BWP/214/96).